Equivalent survival in patients with and without steatosis undergoing resection for colorectal liver metastases following pre-operative chemotherapy

European Journal of Surgical Oncology

Volumn 40, Issue 11, 2014, Pages 1436-1444

  Parkin, E ^a,b   O'Reilly, D A ^a,b   Adam, R ^c   Kaiser, G M ^d   Laurent, C ^e   Elias, D ^f   Capussotti, L ^g   Renehan, A G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^c HÔPITAL PAUL BROUSSE   (France)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e HÔPITAL SAINT ANDRÉ   (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g MAURIZIANO HOSPITAL   (Italy)

Author keywords

Chemotherapy; Colorectal cancer; Liver resection; Survival; Teatosis

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; COLORECTAL LIVER METASTASIS; FATTY LIVER; FEMALE; HUMAN; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER RESECTION; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SURGICAL MORTALITY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; COHORT ANALYSIS; COLORECTAL TUMOR; COMPLICATION; DISEASE FREE SURVIVAL; LIVER; LIVER NEOPLASMS; METASTASIS RESECTION; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FATTY LIVER; FEMALE; HEPATECTOMY; HUMANS; LIVER; LIVER NEOPLASMS; MALE; METASTASECTOMY; MIDDLE AGED; NEOADJUVANT THERAPY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84922481858     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2014.07.040     Document Type: Article

References (38)

1. Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 2010;51:679-89
2. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-7.
3. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288:E462-8.
4. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
5. Renehan A, Tyson M, Egger M, Heller RF, Zwahlen M. Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78.
6. Harriss DJ, Atkinson G, George K, et al. Lifestyle factors and colorectal cancer risk (1): systematic review and meta-analysis of associations with body mass index. Colorectal Dis 2009;11:547-63.
7. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005;200:845-53.
8. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006;24:2065-72.
9. Gomez D, Malik HZ, Bonney GK, et al. Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis. Br J Surg 2007;94:1395-402.
10. Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1, 803 consecutive cases over the past decade. Ann Surg 2002;236:397-406. discussion-7.
11. Pathak S, Tang JM, Terlizzo M, Poston GJ, Malik HZ. Hepatic steatosis, body mass index and long term outcome in patients undergoing hepatectomy for colorectal liver metastases. Eur J Surg Oncol 2010;36:52-7.
12. Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM. Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 1998;2:292-8.
13. Kooby DA, Fong Y, Suriawinata A, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003;7:1034-44.
14. McCormack L, Petrowsky H, Jochum W, Furrer K, Clavien PA. Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg 2007;245:923-30.
15. Terminology Committee of the International Hepato-Pancreato-Biliary Association. Brisbane 2000 terminology of liver anatomy & resections. HPB (Oxford) 2000;2:333-9.
16. de Meijer VE, Kalish BT, Puder M, Ijzermans JN. Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg 2010;97:1331-9.
17. Tamandl D, Klinger M, Eipeldauer S, et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol 2011;18:421-30.
18. Hamady ZZ, Rees M, Welsh FK, et al. Fatty liver disease as a predictor of local recurrence following resection of colorectal liver metastases. Br J Surg 2013;100:820-6.
19. Adam R, Bhangui P, Poston G, et al. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases? Ann Surg 2010;252:774-87.
20. Adam R, Frilling A, Elias D, et al. Liver resection of colorectal metastases in elderly patients. Br J Surg 2010;97:366-76.
21. Andres A, Toso C, Adam R, et al. A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a LiverMetSurvey-based study. Ann Surg 2012;256:772-8. discussion 8-9.
22. Parkin E, O'Reilly DA, Adam R, et al. The effect of hepatic steatosis on survival following resection of colorectal liver metastases in patients without preoperative chemotherapy. HPB (Oxford) 2013;15:463-72.
23. Vigano L, Capussotti L, Barroso E, et al. Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases. Ann Surg Oncol 2012;19:2786-96.
24. Vigano L, Capussotti L, De Rosa G, De Saussure WO, Mentha G, Rubbia-Brandt L. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg 2013;258:731-42.
25. Mullen JT, Ribero D, Reddy SK, et al. Hepatic insufficiency and mortality in 1, 059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 2007;204:854-62. discussion 62-4.
26. Punt CJ, Buyse M, Kohne CH, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007;99:998-1003.
27. Crosbie EJ, Roberts C, Qian W, Swart AM, Kitchener HC, Renehan AG. Body mass index does not influence post-treatment survival in early stage endometrial cancer: results from the MRC ASTEC trial. Eur J Cancer 2012;48:853-64.
28. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008;247:125-35.
29. Little RJA, Rubin DB. Statistical analysis with missing data. 2nd ed. Hoboken: NJ: Wiley; 2002.
30. Wolf PS, Park JO, Bao F, et al. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal Cancer: a single institution experience. J Am Coll Surg 2013;216:41-9.
31. El-Badry AM, Breitenstein S, Jochum W, et al. Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg 2009;250:691-7.
32. Belghiti J. Fatty liver disease as a predictor of local recurrence following resection of colorectal liver metastases (Br J Surg 2013:100:820-826). Br J Surg 2013;100:827.
33. Brouquet A, Nordlinger B. Metastatic colorectal cancer outcome and fatty liver disease. Nat Rev Gastroenterol Hepatol 2013;10:266-7.
34. Lehmann K, Rickenbacher A, Weber A, Pestalozzi BC, Clavien PA. Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg 2012;255:237-47.
35. Ryan P, Nanji S, Pollett A, et al. Chemotherapy-induced liver injury in metastatic colorectal cancer: semiquantitative histologic analysis of 334 resected liver specimens shows that vascular injury but not steatohepatitis is associated with preoperative chemotherapy. Am J Surg Pathol 2010;34:784-91.
36. Brouquet A, Benoist S, Julie C, et al. Risk factors for chemotherapyassociated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases. Surgery 2009;145:362-71.
37. Raptis DA, Fischer MA, Graf R, et al. MRI: the new reference standard in quantifying hepatic steatosis? Gut 2012;61:117-27.
38. Urdzik J, Bjerner T, Wanders A, et al. The value of pre-operative magnetic resonance spectroscopy in the assessment of steatohepatitis in patients with colorectal liver metastasis. J Hepatol 2012;56:640-6.